Biomarin (BMRN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.20
- EPS estimate
- $0.95
- EPS surprise
- +26.98%
- Revenue surprise
- +6.19%
- Revenue
- $989.7M
- Revenue estimate
- $932.0M
- Reported
- Aug 6, 2026
BioMarin reported Q2 2026 results on August 6, 2026. EPS of $1.20 beat the $0.95 estimate by 26.98%. Revenue of $989.7 million was 6.19% above the $932.0 million estimate and the highest in the table. Compared with Q2 2025, revenue rose about 20% from $825.0 million, while EPS dipped about 2% from $1.23.
Revenue has grown steadily, from $408.7 million in Q3 2021 to nearly $1 billion. Annual EPS went from $0.74 in 2022 to $0.88 in 2023 and $2.20 in 2024, then eased to $1.78 in 2025 after losses of $0.16 per share in Q3 2025 and $0.24 in Q4 2025. The first half of 2026 totals $1.96, about 10% below the first half of 2025. The EPS high in the table is $1.23 from Q2 2025. Over the last 20 quarters, BioMarin beat EPS estimates 16 times; the Q4 2025 loss was a 241.68% miss.
Q3 results came between October 26 and November 1 in each of the past five years. That points to late October 2026 for the next report. It will show whether revenue holds near the Q2 level and how EPS compares with the $0.16 loss of Q3 2025.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $0.95 | $1.20 | +26.98% | $989.7M | SEC |
| Q1 2026 | May 4, 2026 | $0.69 | $0.76 | +9.59% | $766.0M | SEC |
| Q4 2025 | Feb 23, 2026 | $0.17 | −$0.24 | −241.68% | $874.6M | SEC |
| Q3 2025 | Oct 27, 2025 | −$0.28 | −$0.16 | +42.88% | $776.1M | SEC |
| Q2 2025 | Aug 4, 2025 | $0.86 | $1.23 | +42.89% | $825.0M | SEC |
| Q1 2025 | May 1, 2025 | $0.71 | $0.95 | +33.03% | $745.1M | SEC |
| Q4 2024 | Feb 19, 2025 | $0.53 | $0.64 | +19.85% | $747.0M | SEC |
| Q3 2024 | Oct 29, 2024 | $0.53 | $0.55 | +3.58% | $745.7M | SEC |
| Q2 2024 | Aug 5, 2024 | $0.36 | $0.55 | +53.72% | $712.0M | SEC |
| Q1 2024 | Apr 24, 2024 | $0.31 | $0.46 | +47.53% | $648.8M | SEC |
| Q4 2023 | Feb 22, 2024 | $0.20 | $0.11 | −44.22% | $646.2M | SEC |
| Q3 2023 | Nov 1, 2023 | $0.22 | $0.21 | −4.33% | $581.3M | SEC |
| Q2 2023 | Jul 31, 2023 | $0.21 | $0.29 | +37.18% | $595.3M | SEC |
| Q1 2023 | Apr 26, 2023 | $0.16 | $0.27 | +74.08% | $596.4M | SEC |
| Q4 2022 | Feb 27, 2023 | −$0.06 | $0.00 | +100.00% | $537.5M | SEC |
| Q3 2022 | Oct 26, 2022 | −$0.01 | −$0.04 | −233.33% | $505.3M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.03 | $0.15 | +355.93% | $533.8M | SEC |
| Q1 2022 | Apr 27, 2022 | $0.21 | $0.63 | +196.47% | $519.4M | SEC |
| Q4 2021 | Feb 23, 2022 | −$0.36 | −$0.32 | +11.72% | $449.8M | SEC |
| Q3 2021 | Oct 27, 2021 | −$0.25 | −$0.20 | +20.03% | $408.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Biomarin (BMRN) last report earnings?
Biomarin last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did BMRN beat earnings estimates?
Yes. Biomarin reported EPS of $1.20 for Q2 2026 against a $0.95 estimate — a 26.98% beat.
How much revenue did BMRN report last quarter?
Biomarin reported $989.7M in revenue for Q2 2026, against a consensus estimate of $932.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.